Trial Profile
Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Clostridium difficile vaccine (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 30 Oct 2016 Results of three year follow up (extension phase) presented at the IDWeek 2016
- 30 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov.
- 26 Dec 2013 Protocol has been amended to add two treatment arms (explore different vaccination schedules using one of formulations)